Literature DB >> 21529810

PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH.

Morgane Baron1, Aurélie S Leroyer, Zouher Majd, Fanny Lalloyer, Emmanuelle Vallez, Kadiombo Bantubungi, Giulia Chinetti-Gbaguidi, Philippe Delerive, Chantal M Boulanger, Bart Staels, Anne Tailleux.   

Abstract

BACKGROUND: Atherosclerosis and non-alcoholic fatty liver disease (NAFLD) are complex pathologies characterized by lipid accumulation, chronic inflammation and extensive tissue remodelling. Microparticles (MPs), small membrane vesicles produced by activated and apoptotic cells, might not only be biomarkers, but also functional actors in these pathologies. The apoE2-KI mouse is a model of atherosclerosis and NAFLD. Activation of the nuclear receptor PPARα decreases atherosclerosis and components of non-alcoholic steatohepatitis (NASH) in the apoE2-KI mouse.
OBJECTIVES: (1) To determine whether MPs are present in atherosclerotic lesions, liver and plasma during atherosclerosis and NASH progression in apoE2-KI mice, and (2) to study whether PPARα activation modulates MP concentrations.
METHODS: ApoE2-KI mice were fed a Western diet to induce atherosclerosis and NASH. MPs were isolated from atherosclerotic lesions, liver and blood and quantified by flow cytometry.
RESULTS: An increase of MPs was observed in the atherosclerotic lesions and in the liver of apoE2-KI mice upon Western diet feeding. PPARα activation with fenofibrate decreased MP levels in the atherosclerotic lesions in a PPARα-dependent manner, but did not influence MP concentrations in the liver.
CONCLUSION: Here we report that MPs are present in atherosclerotic lesions and in the liver of apoE2-KI mice. Their concentration increased during atherosclerosis and NASH development. PPARα activation differentially modulates MP levels in a tissue-specific manner.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529810     DOI: 10.1016/j.atherosclerosis.2011.03.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Emerging role of extracellular vesicles in liver diseases.

Authors:  Harmeet Malhi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-23       Impact factor: 4.052

Review 2.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

Review 3.  Milk fat globule epidermal growth factor VIII signaling in arterial wall remodeling.

Authors:  Mingyi Wang; Hejia H Wang; Edward G Lakatta
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

Review 4.  Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?

Authors:  Morgane Baron; Chantal M Boulanger; Bart Staels; Anne Tailleux
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

Review 5.  Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease.

Authors:  Linda A Ban; Nicholas A Shackel; Susan V McLennan
Journal:  Int J Mol Sci       Date:  2016-03-14       Impact factor: 5.923

6.  Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.

Authors:  Yasushi Honda; Takaomi Kessoku; Yuji Ogawa; Wataru Tomeno; Kento Imajo; Koji Fujita; Masato Yoneda; Toshiaki Takizawa; Satoru Saito; Yoji Nagashima; Atsushi Nakajima
Journal:  Sci Rep       Date:  2017-02-14       Impact factor: 4.379

Review 7.  Review article: vascular effects of PPARs in the context of NASH.

Authors:  Sergi Guixé-Muntet; Louise Biquard; Gyongyi Szabo; Jean-François Dufour; Frank Tacke; Sven Francque; Pierre-Emmanuel Rautou; Jordi Gracia-Sancho
Journal:  Aliment Pharmacol Ther       Date:  2022-06-05       Impact factor: 9.524

Review 8.  Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.

Authors:  Olufunto O Badmus; Sarah A Hillhouse; Christopher D Anderson; Terry D Hinds; David E Stec
Journal:  Clin Sci (Lond)       Date:  2022-09-30       Impact factor: 6.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.